Dr. Ivor R. Elrifi, Ph D., is Chief Executive Officer of Tiziana Life Sciences Ltd from August 19, 2024 and its Executive Director from 2024. Dr. Elrifi is a Member at Mintz, Levin, Cohn, Ferris, Glovsky a...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Gabriele Marco Cerrone	Founder & Executive Chairman	10.8yrs	US$817.00k	36.06% $ 27.7m
Ivor Elrifi	CEO & Executive Director	less than a year	geen gegevens	geen gegevens
Keeren Shah	COO & CFO	less than a year	geen gegevens	geen gegevens
William Clementi	Chief Development Officer	1.3yrs	geen gegevens	geen gegevens
Napoleone Ferrara	Member of Scientific Advisory Board	10.7yrs	geen gegevens	geen gegevens

1.2yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van TLSA wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.2 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Gabriele Marco Cerrone	Founder & Executive Chairman	10.8yrs	US$817.00k	36.06% $ 27.7m
Ivor Elrifi	CEO & Executive Director	less than a year	geen gegevens	geen gegevens
Napoleone Ferrara	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
John Brancaccio	Independent Non-Executive Director	4.5yrs	US$89.00k	geen gegevens
Howard L. Weiner	Chairman of Scientific Advisory Board	9yrs	geen gegevens	geen gegevens
Willy Simon	Independent Non-Executive Director	9.2yrs	US$89.00k	0.0076% $ 5.8k
Arun Sanyal	Member of Scientific Advisory Board	7.8yrs	geen gegevens	geen gegevens
Kevan Herold	Member of Scientific Advisory Board	9yrs	geen gegevens	geen gegevens

9.0yrs

Gemiddelde duur

73yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van TLSA wordt beschouwd als ervaren (gemiddelde ambtstermijn 9 jaar).

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2025/01/08 14:41
Aandelenkoers aan het einde van de dag	2025/01/08 00:00
Inkomsten	2024/06/30
Jaarlijkse inkomsten	2023/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .

Bronnen van analisten

Tiziana Life Sciences Ltd wordt gevolgd door 6 analisten. 0 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Mayank Mamtani	B. Riley Securities, Inc.
Robin Campbell	Equity Development Limited
Raghuram Selvaraju	H.C. Wainwright & Co.

Tiziana Life Sciences Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Tiziana Life Sciences Ltd. Announces Chief Executive Officer Changes

Insufficient new directors

Tiziana Life Sciences Ltd, Annual General Meeting, Dec 14, 2023

Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer, Effective September 1, 2023

Insufficient new directors

Tiziana Life Sciences Ltd Appoints Matthew Davis as Its New Chief Operating Officer

Recent updates

Tiziana Life Sciences: Awaiting Data Of Foralumab For Secondary Progressive Multiple Sclerosis

Tiziana Life Sciences Announces First Patient with Moderate Alzheimer's Disease Dosed with Intranasal Foralumab

Tiziana Life Sciences Ltd Expands Phase 2 Clinical Trial for Non-Active Secondary Progressive Multiple Sclerosis to Additional U.S. Medical Centers

New minor risk - Shareholder dilution

Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study

Tiziana Life Sciences Ltd has filed a Follow-on Equity Offering in the amount of $50 million.

New minor risk - Market cap size

Tiziana Life Sciences Ltd. Announces Chief Executive Officer Changes

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Insufficient new directors

FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis

Tiziana Life Sciences, Ltd. Announces Qualitative Results for All 10 Non-Active Secondary Progressive Multiple Sclerosis (Na-Spms) Patients Enrolled in the Intermediate-Size Patient Population Expanded Access (Ea) Program

Tiziana Life Sciences Ltd announced delayed 20-F filing

Tiziana Life Sciences, Ltd. Announces FDA Allowance for Additional Twenty Patients to Be Enroll in Intranasal Foralumab Multiple Sclerosis Expanded Access Program

Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in Its Expanded Access Program

Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with Pira Highlighted in Neurology

New minor risk - Share price stability

Tiziana Life Sciences Ltd. Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology

Tiziana Life Sciences Ltd. Announces Updated Clinical and Pet Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients

Tiziana Life Sciences Ltd Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation

Tiziana Life Sciences Ltd. Doses First Patient in Phase 2A Trial of Intranasal Foralumab in Multiple Sclerosis

Tiziana Life Sciences Ltd, Annual General Meeting, Dec 14, 2023

Tiziana Life Sciences Ltd. Announces Successfully Enrolled and Dosed Four New Patients with Non-Active Secondary Progressive Multiple Sclerosis

New minor risk - Financial data availability

Tiziana Life Sciences Ltd. Announces Allowance by Fda for At-Home Dosing of Intranasal Foralumab for Multiple Sclerosis Treatment

Tiziana Life Sciences Ltd. Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab

Tiziana Announces Positive Qualitative Six-Month Pet Scan Results with Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed with Non-Active Secondary Progressive MS (Na-SPMS)

Tiziana Life Sciences Ltd. Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis

Will Tiziana Life Sciences (NASDAQ:TLSA) Spend Its Cash Wisely?

Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer, Effective September 1, 2023

New major risk - Share price stability

Insufficient new directors

Tiziana Life Sciences Ltd Appoints Matthew Davis as Its New Chief Operating Officer

New minor risk - Market cap size

Tiziana Life Sciences Ltd. Announces Reduction in Microglial Activation in Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple Sclerosis

We're Keeping An Eye On Tiziana Life Sciences' (NASDAQ:TLSA) Cash Burn Rate

Will Tiziana Life Sciences (NASDAQ:TLSA) Spend Its Cash Wisely?

Tiziana Life Sciences Announces IND Filed for Phase 2 Study of Milciclib in Combination with Gemcitabine for Non-Small Cell Lung Cancer

Tiziana Life Sciences Ltd Announces Additional Clinical Improvements in the Second Patient with Non-Active Secondary Progressive Multiple Sclerosis (Spms) After Eleven Months of Dosing with Intranasal Foralumab

Tiziana Life Sciences Ltd Announces Completion of Prerequisite Pre-Clinical Safety Study

Tiziana Life Sciences Ltd. Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price Requirements

Tiziana Life Sciences Ltd, Annual General Meeting, Dec 29, 2022

Tiziana Life Sciences Ltd Announces Publication of A Peer-Reviewed Article on the Intranasal Administration of Foralumab Demonstrating Modulated Effector CD8+ T Cell Function and an Induced T Cell Regulatory Response in Human Subjects

Less than half of directors are independent

Tiziana Life Sciences Announces Near-Term Strategic Focus on Intranasal Foralumab for Diseases of the Central Nervous System (Cns)

Tiziana Life Sciences Completes Enrollment of the First Patient Cohort for Its Intermediate-Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients

Tiziana Life Sciences Starts Enrollment of the First Patient Cohort in Its Intermediate Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients

Tiziana Life Sciences Ltd. Plans to Submit IND for Phase 1 Trial of Intranasal Foralumab in Alzheimer's Disease Patients

Tiziana Life rises 11% after submitting application to begin human trial of Alzheimer's intranasal therapy

Tiziana chief medical officer further increases holdings in company

Tiziana Life Sciences Ltd Announces Continued Clinical Improvements in the Second Patient with Secondary Progressive Multiple Sclerosis (Spms) After Six Months of Dosing with Intranasal Foralumab

Tiziana Life Sciences Ltd(NasdaqGM:TLSA) dropped from S&P Global BMI Index

Tiziana Life Sciences Announces Grant Received by the Brigham and Women’S Hospital to Explore the Use of Intranasal Anti-Cd3 Mab in Amyotrophic Lateral Sclerosis

Tiziana Life Sciences executive chairman further raises stake in company

Tiziana executive chairman raises stake in company again, buys more shares

Tiziana Life Sciences discloses share purchase by executive chairman

Is Tiziana Life Sciences (NASDAQ:TLSA) In A Good Position To Deliver On Growth Plans?

Less than half of directors are independent

Tiziana Life Sciences Appoints Matthew W. Davis as Chief Medical Officer and Acting Chief Scientific Officer

Tiziana Life Sciences Ltd Announces Resignation of Kunwar Shailubhai as Chief Scientific Officer and Board Director

Tiziana Life Sciences CEO Kunwar Shailubhai resigns

Tiziana Life Sciences Receives Nasdaq Deficiency Notice

Tiziana Life Sciences Announces Positive Clinical Results in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) Following Three Months of Dosing with Intranasal Foralumab

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Rules

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Rules

Less than half of directors are independent

Tiziana Life Sciences Announces FDA Grants Permission to Enroll Up to 8 Additional Secondary Progressive Multiple Sclerosis Patients in the Expanded Access Program with Intranasal Foralumab

Tiziana Life Sciences Ltd Announces Submission of Amendment to Investigational New Drug Application to Advance Oral Foralumab, Fully Human Anti-Cd3 Monoclonal Antibody, in Patients with Crohn’s Disease

Tiziana Life Sciences PLC (NasdaqGM:TLSA) announces an Equity Buyback for $5 million worth of its shares.